The CEO of an Australian IT startup has designed a personalized cancer vaccine for his dog diagnosed with a terminal illness using artificial intelligence (AI) and confirmed its therapeutic effects.

With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...

VanDeMark Chemical is closing a phosgene derivatives plant in Lockport, New York, by May 25, according to a March 4 notice, which says 69 workers will be out of a job. VanDeMark and the Hungarian ...

The Exton-based company provides packaging and related services for injectable drugs. Green led West's pandemic response, supplying packaging for vaccine distribution worldwide.

The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.

Explore how Moderna makes money through its mRNA vaccines, government contracts, and partnerships, and how products like its COVID-19 vaccine drive revenue.

Moderna (NASDAQ: MRNA), Strategy (NASDAQ: MSTR), and Trade Desk (NASDAQ: TTD)—tells three very different stories. All three have bounced off recent lows, but analyst consensus reveals sharply ...

Alnylam CEO Yvonne Greenstreet got an $18M equity award tied to performance through 2029 after the drugmaker's first ...

Seres Therapeutics named former Merck leader Richard N. Kender as executive chair and interim CEO. Urgent care tech company Experity appointed Bobby Ghoshal as CEO. Dana Fox McInerney joined Trevi ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.

The pending resolution "provides certainty going forward for Moderna's full infectious-disease portfolio," the company said, including its newer COVID vaccine, its combination COVID-and-flu shot, and ...